• Yue Wang and Guizhi Zhao.
• Department of Otolaryngology, Daqing Oilfield General Hospital, No. 9 Zhongkang Street, Saltu District, Daqing, 163000, Heilongjiang, China. mingmingnba2022@163.com.
• Ir J Med Sci. 2024 Jun 1; 193 (3): 113711421137-1142.

AimNeurogenic inflammation has been recognized as an important contributing factor in the pathogenesis of allergic rhinitis. The aim of this study was to investigate the clinical values of substance P, vasoactive intestinal peptide (VIP), and neuropeptide Y as biomarkers of disease severity and treatment outcomes of chronic urticaria complicated with allergic rhinitis.MethodsOur prospective study included 150 patients with chronic urticaria complicated with allergic rhinitis and 80 healthy control patients. Before treatment, the serum samples of all study subjects were collected and analyzed using enzyme-linked immunosorbent analysis. The intervention group received imipramine of 10 mg/day orally for 2 weeks, and the Symptom Score Reduction Index (SSRI) was used to analyze clinical outcomes, which were categorized as effectual and ineffectual.ResultsOur data suggested that substance P, VIP, and neuropeptide Y were significantly correlated to each other. Lower levels of substance P, VIP, and neuropeptide Y were associated with better treatment outcomes. A good detection sensitivity (69.49%) and specificity (80.22%) could be achieved using a combination of these markers (area under curve = 0.85).ConclusionsOur data indicates that substance P, VIP, and neuropeptide Y levels before treatment correlate strongly with the treatment outcomes of the patients, which could potentially serve as a decision support tool in clinical management of chronic urticaria complicated with allergic rhinitis.© 2023. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.

28 keywords...

hide…